Luther King Capital Management (LKCM)
ANEB

Luther King Capital Management (LKCM)’s Anebulo Pharmaceuticals ANEB Stock Holding History

Luther King Capital Management (LKCM)’s Portfolio ANEB Stock Details ANEB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-59,662
Closed -$100K – 595
2024
Q4 		$100K Buy
+59,662
New +$98.3K ﹤0.01% 582

Other funds holding ANEB

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Luther King Capital Management (LKCM)'s ANEB Position: Q1 2025 in Review

Luther King Capital Management (LKCM) sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2025, closing a stake of 59,662 shares — an estimated $100K sold.

Luther King Capital Management (LKCM) first reported a position in ANEB in Q4 2024 and held it in 1 quarter. The position peaked at $100K in Q4 2024. 18 funds tracked by Wall St. Rank hold ANEB as of Q1 2025.

  • Luther King Capital Management (LKCM) reported no remaining Anebulo Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Luther King Capital Management (LKCM) sold 59,662 Anebulo Pharmaceuticals shares in Q1 2025, an estimated $100K.
  • Luther King Capital Management (LKCM) first reported a position in Anebulo Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Luther King Capital Management (LKCM)'s Anebulo Pharmaceuticals position peaked at $100K in Q4 2024.
  • 18 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2025.

Based on Luther King Capital Management (LKCM)'s 13F filing for Q1 2025, filed 12 May 2025.